Cargando…

National Incidence, Management and Survival of Urachal Carcinoma

Urachal carcinoma is an uncommon cancer whose rarity has precluded its study and evidence-based management strategies are lacking. This study assessed all urachal carcinomas in Ireland and clinical parameters in order to improve understanding. Urachal carcinomas diagnosed from 1994 to 2011 were iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Dearbhaile C., Velázquez-Kennedy, Kyra, Deady, Sandra, Brady, Adrian P., Sweeney, Paul, Power, Derek G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064294/
https://www.ncbi.nlm.nih.gov/pubmed/27746878
http://dx.doi.org/10.4081/rt.2016.6257
_version_ 1782460128453197824
author Collins, Dearbhaile C.
Velázquez-Kennedy, Kyra
Deady, Sandra
Brady, Adrian P.
Sweeney, Paul
Power, Derek G.
author_facet Collins, Dearbhaile C.
Velázquez-Kennedy, Kyra
Deady, Sandra
Brady, Adrian P.
Sweeney, Paul
Power, Derek G.
author_sort Collins, Dearbhaile C.
collection PubMed
description Urachal carcinoma is an uncommon cancer whose rarity has precluded its study and evidence-based management strategies are lacking. This study assessed all urachal carcinomas in Ireland and clinical parameters in order to improve understanding. Urachal carcinomas diagnosed from 1994 to 2011 were identified from the National Cancer Registry in Ireland. Data obtained included patient age, gender, diagnostic year, pathology, tumor stage, patient treatment strategies and survival. Twenty-six urachal carcinomas were identified, the majority being adenocarcinoma. This comprised 0.3% of all invasive bladder tumors. Patients were predominantly male (62%) and over 50 years of age (58%). Twenty-two patients (85%) underwent surgery, with only six (23%) undergoing chemotherapy. On average, median overall survival was 2.6 years (range 0-15.2 yrs). Survival was longer in women (5 vs. 1.9 yrs), patients under 50 years of age (3.6 vs. 1.9 yrs), those without confirmed metastasis (4.1 vs. 0.7 yrs) and those who received chemotherapy (3.6 vs. 2.6 yrs). The overall survival of urachal carcinoma in Ireland is less than expected from published literature. This study highlights the need for centralization of rare tumors with international collaboration to identify the optimal treatment strategy and improve outcome.
format Online
Article
Text
id pubmed-5064294
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-50642942016-10-14 National Incidence, Management and Survival of Urachal Carcinoma Collins, Dearbhaile C. Velázquez-Kennedy, Kyra Deady, Sandra Brady, Adrian P. Sweeney, Paul Power, Derek G. Rare Tumors Article Urachal carcinoma is an uncommon cancer whose rarity has precluded its study and evidence-based management strategies are lacking. This study assessed all urachal carcinomas in Ireland and clinical parameters in order to improve understanding. Urachal carcinomas diagnosed from 1994 to 2011 were identified from the National Cancer Registry in Ireland. Data obtained included patient age, gender, diagnostic year, pathology, tumor stage, patient treatment strategies and survival. Twenty-six urachal carcinomas were identified, the majority being adenocarcinoma. This comprised 0.3% of all invasive bladder tumors. Patients were predominantly male (62%) and over 50 years of age (58%). Twenty-two patients (85%) underwent surgery, with only six (23%) undergoing chemotherapy. On average, median overall survival was 2.6 years (range 0-15.2 yrs). Survival was longer in women (5 vs. 1.9 yrs), patients under 50 years of age (3.6 vs. 1.9 yrs), those without confirmed metastasis (4.1 vs. 0.7 yrs) and those who received chemotherapy (3.6 vs. 2.6 yrs). The overall survival of urachal carcinoma in Ireland is less than expected from published literature. This study highlights the need for centralization of rare tumors with international collaboration to identify the optimal treatment strategy and improve outcome. PAGEPress Publications, Pavia, Italy 2016-10-05 /pmc/articles/PMC5064294/ /pubmed/27746878 http://dx.doi.org/10.4081/rt.2016.6257 Text en ©Copyright D.C. Collins et al. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Collins, Dearbhaile C.
Velázquez-Kennedy, Kyra
Deady, Sandra
Brady, Adrian P.
Sweeney, Paul
Power, Derek G.
National Incidence, Management and Survival of Urachal Carcinoma
title National Incidence, Management and Survival of Urachal Carcinoma
title_full National Incidence, Management and Survival of Urachal Carcinoma
title_fullStr National Incidence, Management and Survival of Urachal Carcinoma
title_full_unstemmed National Incidence, Management and Survival of Urachal Carcinoma
title_short National Incidence, Management and Survival of Urachal Carcinoma
title_sort national incidence, management and survival of urachal carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064294/
https://www.ncbi.nlm.nih.gov/pubmed/27746878
http://dx.doi.org/10.4081/rt.2016.6257
work_keys_str_mv AT collinsdearbhailec nationalincidencemanagementandsurvivalofurachalcarcinoma
AT velazquezkennedykyra nationalincidencemanagementandsurvivalofurachalcarcinoma
AT deadysandra nationalincidencemanagementandsurvivalofurachalcarcinoma
AT bradyadrianp nationalincidencemanagementandsurvivalofurachalcarcinoma
AT sweeneypaul nationalincidencemanagementandsurvivalofurachalcarcinoma
AT powerderekg nationalincidencemanagementandsurvivalofurachalcarcinoma